Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 배상철 | - |
dc.date.accessioned | 2018-03-24T01:58:06Z | - |
dc.date.available | 2018-03-24T01:58:06Z | - |
dc.date.issued | 2013-10 | - |
dc.identifier.citation | International Journal of Rheumatic Diseases, 2013, 16(5), P.527-531 | en_US |
dc.identifier.issn | 1756-1841 | - |
dc.identifier.issn | 1756-185X | - |
dc.identifier.uri | http://onlinelibrary.wiley.com/doi/10.1111/1756-185X.12154/abstract;jsessionid=38897254077C13A306BFA3985F5A34B4.f03t01 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/51721 | - |
dc.description.abstract | ObjectiveThe aim of this study was to assess the effects of anti-tumor necrosis factor (TNF) agents or disease-modifying antirheumatic drugs (DMARDs) on hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-positive patients with rheumatic diseases.MethodsEvidence of HBV reactivation after anti-TNF therapy or DMARDs in HBsAg-positive patients with rheumatic disease was summarized by performing a systematic review.ResultsA total of 122 HBsAg-positive rheumatic disease-positive patients undergoing treatment with an anti-TNF agent or with DMARDs were identified in nine studies. In eight of the studies, the anti-TNF agents used were etanercept in 56 cases, adalimumab in 25 cases and infliximab in 14 cases. Follow-up periods ranged from 6 to 52 months. Antiviral prophylaxis was administrated in 48 of the 122 patients (39.3%). HBV reactivation in HBsAg-positive patients taking an anti-TNF agent or DMARD was reported in 15 cases (15/122 = 12.3%). Ten of the 15 patients provided individual data on HBV reactivation: four patients had rheumatoid arthritis, four had ankylosing spondylitis and two had psoriatic arthritis; four received etanercept, and two received infliximab. In one of the four etanercept-treated cases in which the patient had elevated HBV-DNA levels, antiviral prophylaxis was also administered. Antiviral treatment was also administered in seven patients receiving other treatments: lamivudine in one, adefovir in one and entecavir in five. Clinical outcomes were satisfactory in all 10 cases of HBV reactivation.ConclusionsHepatitis B virus reactivation was found in 15 (12.3%) patients among the 122 HBsAg-positive patients with rheumatic diseases treated with anti-TNF agents or DMARDs. | en_US |
dc.description.sponsorship | This study was supported by a grant from the Korean Healthcare Technology R&D Project, Korean Ministry of Health and Welfare (A102065). | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY-BLACKWELL | en_US |
dc.subject | anti?tumor necrosis factor therapy | en_US |
dc.subject | DMARD | en_US |
dc.subject | hepatitis B virus reactivation | en_US |
dc.subject | rheumatic diseases | en_US |
dc.subject | FACTOR-ALPHA ANTAGONISTS | en_US |
dc.subject | HBV REACTIVATION | en_US |
dc.subject | RETROSPECTIVE ANALYSIS | en_US |
dc.subject | ARTHRITIS PATIENTS | en_US |
dc.subject | INFECTION | en_US |
dc.subject | SAFETY | en_US |
dc.subject | PSORIASIS | en_US |
dc.subject | CARRIERS | en_US |
dc.subject | AGENTS | en_US |
dc.title | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs | en_US |
dc.type | Article | en_US |
dc.relation.volume | 16 | - |
dc.identifier.doi | 10.1111/1756-185X.12154 | - |
dc.relation.page | 527-531 | - |
dc.relation.journal | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.contributor.googleauthor | Lee, Young Ho | - |
dc.contributor.googleauthor | Bae, Sang-Cheol | - |
dc.contributor.googleauthor | Song, Gwan Gyu | - |
dc.relation.code | 2013004088 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | scbae | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.